A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers
Georg Golor1, Ke Hu2, Matthieu Ruffin3, Alexandra Buchelt3, Emmanuel Bouillaud3, Yanfeng Wang2, Mario Maldonado31Parexel International GmbH, Berlin, Germany; 2Novartis Pharmaceuticals, East Hanover, NJ, USA; 3Novartis Pharma AG, Basel, SwitzerlandAbstract: Pasireotide (SOM230) is a multireceptor-tar...
Saved in:
Main Authors: | Golor G (Author), Hu K (Author), Ruffin M (Author), Buchelt A (Author), Bouillaud E (Author), Wang Y (Author), Maldonado M (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2012-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Estrogens Modulate Somatostatin Receptors Expression and Synergize With the Somatostatin Analog Pasireotide in Prostate Cells
by: Valentina Rossi, et al.
Published: (2019) -
Corrigendum: Estrogens modulate somatostatin receptors expression and synergize with the somatostatin analog pasireotide in prostate cells
by: Valentina Rossi, et al.
Published: (2024) -
Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues
by: Wolin EM, et al.
Published: (2015) -
Patients' satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
by: Christina Darden, et al.
Published: (2021) -
Pasireotide: a novel treatment for patients with acromegaly
by: Cuevas-Ramos D, et al.
Published: (2016)